Related Experiment Video
Updated: Jan 7, 2026

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
Published on: April 18, 2025
Plasma proteomic profiles reveal immune modulation by immunonutrition in GI cancer
Semíramis Silva Santos1, Lucianna Auxi Teixeira Josino da Costa2, Tamara Soares de Oliveira Araripe3
1Cancer Institute of Ceará (ICC), Fortaleza, Ceará, Brazil; RENORBIO, State University of Ceará (UECE), Fortaleza, Ceará, Brazil.
Background:
Gastrointestinal (GI) cancer patients undergoing surgery often face immunosuppression, increasing postoperative risk. Immunomodulatory enteral nutrition (IEN) may enhance immune function and recovery, but mechanisms remain unclear. This study compared plasma proteomic profiles of patients receiving IEN versus standard enteral nutrition (SEN) to explore pathways linked to outcomes.
Methods:
This analysis extended a previously published randomized clinical trial in GI cancer patients who received SEN or IEN postoperatively, with 50 patients in each group. The IEN was rich in arginine, nucleotides, vitamin B12, chloride, vitamin C, selenium, chromium, and molybdenum. Plasma samples were analyzed using mass spectrometry-based proteomics (MassLynx v4.1 and Progenesis v4.1). Proteins consistently detected across replicates (database search P < 0.05) were identified. Clinical outcomes, including complications and biochemical markers, were integrated with proteomic findings to interpret biological mechanisms.
Results:
Distinct proteomic profiles were observed. The IEN group showed higher levels of complement proteins (C3, C5, C9), inter-alpha-trypsin inhibitor heavy chain H2, pregnancy zone protein, immunoglobulins, and apolipoproteins-proteins linked to immune modulation, tissue repair, and inflammation control. The SEN group displayed elevated acute-phase proteins and coagulation factors, including fibrinogen and serum amyloid A-4, consistent with a pro-inflammatory, hypercoagulable state. These differences paralleled clinical results, with the IEN group experiencing fewer complications and improved albumin/globulin ratios.
Conclusions:
This exploratory study suggests that immunonutrition may modulate complement activation and immune pathways, supporting better postoperative outcomes in GI cancer patients. The proteomic profile provides evidence that supports a mechanistic hypothesis underlying the observed clinical benefits. Future quantitative proteomics with larger cohorts is warranted to validate these findings and optimize perioperative nutrition strategies.
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Psychoneuroimmunology: Diabetes and Cancer

